Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

Table 1 Demographics and baseline characteristics for participants who responded to treatment

Characteristic	EM responders^a		CM responders^b
Characteristic	Quarterly fremanezumab (n = 214)	Monthly fremanezumab (n = 215)	Quarterly fremanezumab (n = 218)	Monthly fremanezumab (n = 210)
Age, mean ± SD, y	41.4 ± 11.7	43.1 ± 12.2	41.9 ± 12.7	41.3 ± 11.9
Body mass index, mean ± SD, kg/cm²	26.9 ± 5.2	26.3 ± 5.4	26.7 ± 5.3	26.5 ± 5.0
Male sex, n (%)	29 (14)	34 (16)	22 (10)	24 (11)
Race, n (%)
White	171 (80)	178 (83)	171 (78)	171 (81)
Black/African American	21 (10)	17 (8)	20 (9)	16 (8)
Asian	20 (9)	18 (8)	22 (10)	21 (10)
Other	2 (< 1)	2 (< 1)	5 (2)	2 (< 1)
Disease history
Years since initial migraine diagnosis, mean ± SD	19.9 ± 11.9	20.5 ± 12.8	20.0 ± 12.6	19.8 ± 11.2
Current preventive medication use, n (%)	40 (19)	44 (20)	41 (19)	45 (21)
Current use of acute headache medication, n (%)	209 (98)	212 (99)	210 (96)	199 (95)
Disease characteristics
Monthly migraine days,^c mean ± SD	9.3 ± 2.5	9.1 ± 2.6	16.3 ± 4.6	16.0 ± 4.7
Headache days of any severity,^d mean ± SD	8.5 ± 3.2	8.1 ± 3.2	15.5 ± 5.7	15.5 ± 5.5
Monthly days of acute headache medication use, mean ± SD	7.9 ± 3.6	7.9 ± 3.3	13.0 ± 6.6	13.3 ± 6.9
MIDAS score	n = 201	n = 205
Mean ± SD, points	39.2 ± 32.1	37.0 ± 33.4	N/A	N/A
HIT-6 score			n = 204	n = 202
Mean ± SD, points	N/A	N/A	64.3 ± 5.0	64.9 ± 4.5
MSQoL domain score, mean ± SD, points	n = 211	n = 212	n = 215	n = 208
EF	64.9 ± 23.2	65.5 ± 24.4	57.3 ± 26.4	58.3 ± 25.6
RFP	71.0 ± 17.9	71.7 ± 17.6	66.2 ± 21.1	67.3 ± 21.3
RFR	56.5 ± 16.3	57.3 ± 16.0	47.7 ± 18.6	49.0 ± 18.9

CM Chronic migraine, EF Emotional function, EM Episodic migraine, HIT-6 The 6-item Headache Impact Test, MIDAS Migraine Disability Assessment, MSQoL Migraine-Specific Quality of Life, N/A Not applicable, RFP Role function–preventive, RFR Role function–restrictive, SD Standard deviation, MAMD Monthly average migraine days
^aResponders are defined as participants with EM who had a reduction of ≥2 MAMD
^bResponders are defined as participants with CM who had a reduction of ≥4 MAMD
^cA migraine day was defined as a calendar day in which headache pain lasted ≥4 consecutive hours and met criteria for migraine (with or without aura) or probable migraine (subtype in which only 1 migraine criterion is absent), or a day in which acute migraine–specific medication (triptans or ergots) was used to treat a headache of any duration
^dA headache day was defined as a calendar day in which headache pain lasted at least 4 consecutive hours and had a peak severity of at least a moderate level, or a day in which acute migraine–specific medication (triptans or ergots) was used to treat a headache of any severity or duration

ISSN: 1129-2377